On July 9, 2017 Laekna reported that it acquired the global rights from Novartis Pharma AG to develop, manufacture and commercialize small molecule candidate LAE001 (previously known as CFG920) for prostate cancer (Press release, Laekna Therapeutics, JUL 9, 2017, View Source;article_id=14 [SID1234530439]). LAE001 has been previously studied in phase II clinical trial in the United States, and demonstrated satisfactory efficacy and safety profile in metastatic castration prostate cancer patients. Laekna are committed to deliver this drug further to regulatory approval in China and the rest of the world

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!